McNiece Ian K, Wacker Kara K, Kurtzberg Joanne, Warkentin Phyllis I
CellMED Consulting, Coral Gables, Florida, USA; Regenerative Medicine Task Force, Foundation for the Accreditation of Cellular Therapy at the University of Nebraska Medical Center, Omaha, Nebraska, USA.
Foundation for the Accreditation of Cellular Therapy at the University of Nebraska Medical Center, Omaha, Nebraska, USA; Regenerative Medicine Task Force, Foundation for the Accreditation of Cellular Therapy at the University of Nebraska Medical Center, Omaha, Nebraska, USA.
Cytotherapy. 2021 Oct;23(10):886-893. doi: 10.1016/j.jcyt.2021.02.004. Epub 2021 Mar 26.
Cell and gene therapy is a promising and disruptive new field of medicine for diseases lacking effective treatments. Collaboration among stakeholders has become critically important as investigators, health care providers, manufacturers, couriers, data registries, regulators and payers all become more invested in the success of this field. Many organizations have collaborated with each other to increase clarity, advocate for improvements and share lessons learned. These efforts appear to be making an impact, although the potential for duplicative efforts could slow progress. The second Regenerative Medicine InterCHANGE, hosted by the Foundation for the Accreditation of Cellular Therapy, took place at the Phacilitate Leaders World/World Stem Cell Summit conference in Miami, Florida, on January 24, 2020. Participants from several organizations outlined needs to advance cell and gene therapies. Efforts to address these include standardization, workforce development and advocacy. This article summarizes the major challenges and opportunities discussed during the InterCHANGE.
细胞和基因疗法是针对缺乏有效治疗方法的疾病的一个充满前景且具有颠覆性的新医学领域。随着研究人员、医疗保健提供者、制造商、快递员、数据登记机构、监管机构和支付方都更加致力于该领域的成功，利益相关者之间的合作变得至关重要。许多组织相互合作以提高清晰度、倡导改进并分享经验教训。这些努力似乎正在产生影响，尽管重复努力的可能性可能会减缓进展。由细胞治疗认证基金会主办的第二届再生医学交流会于2020年1月24日在佛罗里达州迈阿密举行的Phacilitate Leaders World/World Stem Cell Summit会议上举行。来自多个组织的参与者概述了推进细胞和基因疗法的需求。为解决这些问题所做的努力包括标准化、劳动力发展和宣传。本文总结了交流会上讨论的主要挑战和机遇。
